Samsung Biologics expands into preclinical research with the launch of Samsung Organoids, offering advanced 3D drug screening services to boost precision medicine.
 |
| Samsung Biologics unveils Samsung Organoids, a breakthrough in preclinical drug screening aimed at improving drug efficacy and enabling personalized therapies. Image: SB/ CH |
INCHEON, South Korea — June 16, 2025:
Samsung Biologics, a global leader in contract development and manufacturing (CDMO), has announced the launch of Samsung Organoids, an innovative drug screening platform designed to accelerate drug discovery and improve clinical outcomes. The new service marks the company’s strategic expansion into preclinical research.
Organoids are advanced three-dimensional (3D) cell culture models that replicate the structure and function of human organs with remarkable accuracy. These miniaturized, lab-grown models enable researchers to predict patient-specific drug responses, streamline preclinical workflows, and make more informed lead candidate selections, significantly enhancing the precision of therapeutic development.
The introduction of Samsung Organoids allows the company to offer precision screening tools capable of delivering data-driven insights during the early phases of drug development. By integrating high-throughput organoid analysis into its service pipeline, Samsung aims to assist clients in accelerating investigational new drug (IND) filings and reducing risk in clinical trials.
“This launch demonstrates our commitment to innovation and advancing personalized medicine,” said John Rim, CEO and President of Samsung Biologics. “Samsung Organoids enhances our ability to support the entire drug development life cycle—right from discovery to commercialization—with deeper therapeutic insights and improved efficiency.”
The launch extends Samsung Biologics’ service portfolio to now include target discovery, lead optimization, preclinical development, and clinical trial planning. The company is leveraging its robust scientific and manufacturing infrastructure—including a combined 784 kL biomanufacturing capacity across five facilities—to deliver solutions across multiple therapeutic modalities. These include multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA-based treatments.
Samsung Biologics operates a global footprint, with operations and offices in South Korea, the United States, and Japan. Its Samsung Biologics America division serves clients in the U.S. and Europe, while its Tokyo office strengthens engagement across the Asia-Pacific region.
In addition to expanding its technological reach, Samsung Biologics continues to prioritize sustainability, product quality, and agile delivery, reinforcing its reputation as a premier partner in biopharmaceutical development.
The launch of Samsung Organoids is expected to open new frontiers in personalized and precision medicine, offering clients more accurate tools for decision-making and contributing to the advancement of global healthcare.